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The Indo-US symposium on Blastocyst Research concluded with a round table 
discussion on trends in research with particular relevance to the development of 
contraceptives. A number of events crucial to the initiation and maintenance of 
implantation were identified and possibilities of developing a contraceptive modality 
based on interference with these events in implantation were discussed.
There is a great demand from women and national family planning programmes for 
simple, effective and safe methods of fertility regulation which can be self-administered 
either post-coitally or for use when menses are delayed by a few days. The availability of 
such contraceptive technology would limit exposure to fertility regulating agents only 
to such occasions when coitus takes place or when there is a probability of pregnancy. 
Moreover, if fertilization had indeed occurred, interruption would take place at the 
earliest stage of pregnancy thereby reducing the excessive bleeding encountered with 
later termination of pregnancy. Methods of post-coital contraception used so far have 
been reserved primarily for emergency situations to protect women from unwanted
pregnancy resulting from rape or acts of unprotected coitus or failed barrier methods.
Probabilities that an act of coitus will lead to conception, with reference to the 
estimated time of ovulation, is highest during the fertile period (9·6+ 2·6 days). The 
objective of any form of contraception related to coitus would be to interfere with 
implantation irrespective of the day when the drug is taken. A drug effective in 
inhibiting implantation during the most fertile period is likely to be effective in other 
periods of the menstrual cycle also. 
The areas selected for discussion were: 
 
 
 
Uterine sensitivity 
 
—What are the factors that regulate uterine sensitivity and maternal recognition of 
the blastocyst? 
—What are the factors involved in the development of uterine refractoriness? Can 
refractoriness be induced? 
—Are there specific uterine and blastocyst proteins involved in implantation? 
—Is induction of a short luteal phase a possible approach to modify uterine 
environment and render it hostile for implantation?
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Blastocyst 
 
—What is the role of estrogens (ovarian or produced by the blastocyst) in 
implantation? Can this be interfered with by antiestrogens administered systemi- 
cally? What is the role of catechol estrogens in implantation?
 
Luteolysis 
 
Research needs, animal models, status of R and D with methods to inhibit implantation 
and disruption of established implantation.
 
Uterine sensitivity: 
 
Initiation of implantation is dependent on a coordinated series of events in the uterus 
triggered by the sequential action of estrogens and progesterone secreted by the ovary 
during the pre, peri and post-ovulatory period. Uterine sensitivity and receptivity to 
implantation is variable in different species and is perhaps less than two days during the 
fertile period in the human. At other times in the menstrual cycle, the uterine 
environment is hostile to the implantation of the blastocyst. Refractoriness is a 
condition when the process of decidualization does not occur in rodents. The 
biochemical basis for the development of uterine sensitivity/refractoriness is not fully 
understood in non-human primates and human. The generation, storage and release of 
vasodilatory mediators, catechol amines (endometrial monoamine oxidase and 
catechol-O-methyl transferase involved in catechol amine deactivation), prostaglan- 
dins, cathepsins, phospholipase A etc., appear to be involved in the modulation of 
uterine vascular functions and uterine sensitivity. The crucial question is the 
identification of factor/s involved in the onset of uterine refractoriness and whether 
such a condition can be induced. Recent studies in baboons have led to the isolation of a 
low molecular weight substance (400–500 daltons) from the refractory uterus which 
appears to be toxic. Further studies are required to confirm and extend these 
observations in other non-human primates and human. Biochemical marker/s for the 
recognition of the refractory period need to be identified.
The uterine epithelium and subepithelial stroma destined to decidualize show a 
differential temporal response to the action of estrogen and progesterone. A number of 
proteins synthesized by the luminal epithelial cells in response to estrogens to achieve 
sensitivity have been identified but the specificity of any of these to implantation is not 
established. Likewise, a number of proteins secreted by the unimplanted blastocyst 
have been isolated, but the role of none of these, other than human chorionic 
gonadotropin (hCG), has been clarified. It is unlikely that any of the presently known 
uterine/blastocyst proteins can be used to develop an immunological approach to 
interfere with implantation. hCG subunits or smaller peptides of hCG constitute the 
basis for the only immunological approach to interfere with implantation which is 
under development. There is need for the development of an in-vitro model to culture 
the endometrium in different phases of the menstrual cycle with the blastocyst to 
elucidate the biochemical entities involved in the interaction between the two. Such a
model would also permit analysis of the sequential events and concurrent biochemical
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changes associated with implantation, viz, apposition, adhesion and penetration.
It is desirable to modify uterine sensitivity to implantation by simulating naturally
occurring condition of ‘short luteal phase’ which is generally associated with infertile 
cycles. Such a condition has been induced in the rhesus monkey by reduction of folical 
stimulating hormone (FSH) in the follicular phase. This leads to disruption of the luteal 
phase and reduction in levels of progesterone. This is an area in which further work is 
needed. 
One of the methods to modify uterine sensitivity is to interfere with the action of 
progesterone on the endometrium. A progesterone antagonist or antiprogestin, taken 
orally during very early pregnancy or after missed menses could, by binding to 
endometrial progesterone receptors, interfere with the maintenance of the secretory 
endometrium essential for the continuation of pregnancy. One of these compounds, 
RU-38486 has received considerable attention recently and is being evaluated clinically. 
An antiprogesterone monoclonal antibody has been shown to inhibit implantation in 
mice possibly due to the reduction by the progesterone antibody of readily available 
progesterone in circulation for maintaining uterine sensitivity for implantation. The 
acceptability/safety of a passive immunization method and its efficacy in other species 
remains to be established.
 
 
Blastocyst 
 
Interaction between the blastocyst and uterus is essential for the initiation and 
maintenance of implantation. The role of estrogen produced by the ovary (which 
appears in the form of a second peak during the week following ovulation in women) to 
the initiation of implantation is not clear. Estrogen of embryonic/endometrial origin 
has been implicated in the process of maternal recognition in several species including 
the rat, mouse, rabbit, pig and hamster but remains to be demonstrated in the non- 
human primates and human. Implantation in the hamster is considered to be solely 
dependent on progesterone but it has recently been shown that the number of 
implantation sites increase with estrogen supplementation. The steroidogenic activity 
of the embryo and the endometrium shows wide qualitative and quantitative species 
variations. The role of these local estrogens at the time of implantation is not clear. The 
blastocyst secretes several proteins besides estrogens, viz, proteins (hCG is the most 
well defined), catechol estrogens and several enzymes. A specific ovine trophoblastic 
protein besides prolonging the function of the corpus luteum, interacts with the 
endometrium by altering the pattern of protein synthesis by endometrial explants 
cultured in vitro. The presence and role of similar proteins in non-human primates 
remain to be established.
Steroidal and non-steroidal antiestrogens administered systemically post-coitally 
inhibit implantation in the rat but are ineffective in the hamsters and primates.
However, antiestrogens administered intraluminally into the uterine lumen post-
coitally interfere with implantation in the hamster, a species which is not dependent on 
ovarian estrogen for implantation. This has been interpreted as evidence for the role of
estrogen secreted by the blastocyst in triggering implantation in the hamster. The 
failure of antiestrogens to inhibit implantation in non-human primates may be due to 
the insufficient dose and/or time of administration of the compounds. Zuclomiphene, a
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potent antiestrogen, administered to rhesus monkeys between days 5–11 of the cycle at 
doses which do not affect hypothalamic function, inteferes with fertility of the treated 
females. It is necessary to evaluate the effects of antiestrogens administered at different 
stages in the menstrual cycle of non-human primates specially during the week 
following ovulation and mating. Catechol estrogens which represent metabolites of 
estrogens, are secreted by the blastocyst (rabbit) and may mediate in the stimulatory 
effects of estrogens on prostaglandin synthesis in the embryo and/or uterus and thus 
participate in the establishment of implantation. Catechol estrogens are formed 
uniquely in the embryo and it should therefore be possible to selectively interfere with 
the blastocyst by inhibitors/antagonists of catechol estrogens. However, such com- 
pounds need to be synthesized and evaluated.
 
Luteolysis: 
 
The role of prostaglandins in implantation is not fully established. Earlier studies 
indicate a luteolytic role for prostaglandins (PGs) in a few species of animals other than 
non-human primates. The role of PGs in capillary permeability has been studied. If 
implantation is considered to involve inflammatory and immunosuppressant actions, 
perhaps PG-E2 can do both, but in reality this class of PGs does not interfere with 
implantation. The cyclooxygenase system has been studied in relation to implantation 
recently. Leucotrienes have been identified in the blastocyst and these are known to 
have chemotactic action. Are these involved in the initiation of attachment of the 
blastocyst? This is an interesting area for further studies.
Monoclocal antibodies to LHRH agonist have been reported to terminate pregnancy 
in baboons when administered around the periimplantation period. It is suggested that 
this effect may be due to the direct effects on the trophoblast. Considerable work is 
needed to confirm this effect and establish the safety of a passive immunization 
approach for fertility regulation.
Luteinizing hormone receptor binding inhibitors (LHRBI) have been isolated from 
the follicular fluid and corpora lutea. The identity of these compounds, purification and 
demonstration of their effects in vivo need many years of basic research before they can 
be considered for use in regulation of fertility.
Deglycosylated derivatives of hCG have been shown to antagonize the action of 
hCG and interfere with established pregnancy in rats. Studies on the stability of the 
derivatives and their effects on the termination of pregnancy in non-human primates 
are in progress. Appropriate methods of delivery, possible immunogenicity and 
alternate methods of production of hCG need to be studied before evaluation of the 
derivatives for clinical use. 
 
Research needs 
 
There are a number of gaps in our knowledge of the processes regulating implantation 
which need to be investigated. Some of these are indicated in the preceeding discussion. 
Other areas are: 
 
—changes in the concentration of steroid receptors during the peri- and post- 
implantation period. 
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—are there any enzymes secreted by the blastocyst which are unique and crucial to 
the initiation of implantation?  
—whether the functional life of the corpus luteum can be prolonged by hCG 
administration, if so, for how long? Such a model would be useful in screening 
luteolytic agents.  
—There are at present no biochemical markers for the prediction of implantation. It 
is necessary to determine if some of the proteins secreted by the preimplantation 
blastocyst enter the saliva/urine and can be detected by simple tests. hCG has been 
detected in the preimplanting blastocyst but a diagnostic and sensitive test to 
determine its presence in saliva/urine as a method to predict implantation remains 
to be developed. 
—develop more potent luteolytic agents. Deglycosylated hCG needs to be evaluated 
in non-human primates. 
—Progesterone receptor blockers: recent reports on the development of a potent 
progesterone receptor blocker interfering with early pregnancy has evoked 
considerable interest in these compounds. There is need for the initiation of a 
programme of synthesis and evaluation of new classes of antiprogestins (steroidal 
or non-steroidal) based on an understanding of the structure of the progesterone 
receptor. 
 
 
Animal models 
 
It is most unlikely that any of the rodent or non-human primate species will prove ideal 
as a model for all aspects of implantation in the human. It may be necessary to carry out 
some studies in the human after obtaining clearance from the appropriate Ethics 
Committees of the institutions where such studies are carried out and without 
compromising safety. Non-human primates are preferred for the reason that they are 
close to the human but their widespread use depends on a number of factors such as 
availability, cost, ease of management and captive breeding performance. It is necessary 
to establish international collaboration between countries/institutions where primate 
facilities exist to optimize their use in research on regulation of fertility. Likewise, there 
is need for standardization of methods and models and exchange of scientists and 
information to achieve the objectives outlined earlier.
 
 
Status of research and development with post-coitals and menses inducers 
 
Methods of post-coital contraception used so far include IUD’s inserted post-coitally, 
estrogens used alone or in combination with estrogens. These are reserved primarily for 
emergency situations to protect women from unwanted pregnancy. Levonorgestrel 
which has shown satisfactory contraceptive efficacy is being further evaluated clinically. 
Centchroman, a non-steroidal drug has been evaluated clinically as a once-a-week pill 
but its future as a fertility regulating agent depends on re-evaluation of its toxicology 
and determination of a suitable dose to avoid undesirable side effects.
Menstrual regulation could be achieved by a number of approaches: (a) block 
progesterone receptors and interfere with the preparation of the uterus for implan-
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tation, (b) luteolysis leading to decreased progesterone levels and interruption of 
pregnancy and (c) termination of early pregnancy by prostaglandin analogues. A 
number of progesterone antagonists have been evaluated clinically. One of these 
compounds, RU-38486 has received considerable attention recently and is being 
evaluated clinically for termination of early pregnancy. Preliminary results seem to 
indicate that the drug, even in high doses, may not result in complete evacuation of the 
product of conception. A number of prostaglandin analogues are being evaluated 
clinically for termination of early pregnancy specially under conditions when they are 
self-administered at home. 
It is perhaps reasonable to expect that a post-coital pill or a menstrual regulating 
agent based on ongoing clinical studies may be available for general use before the end 
of the decade. However, any method based on new leads which may emerge from basic 
research studies is unlikely to be available for clinical use in regulation of fertility before 
the turn of the century. 
 
